KLIFO
KLIFO is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at KLIFO.
KLIFO is a company.
Key people at KLIFO.
Key people at KLIFO.
KLIFO is a leading Danish drug development consultancy and full-service Clinical Trial Supply provider, partnering with pharmaceutical and biotech companies to advance projects from early development to market approval.[1][2][3] It offers end-to-end multidisciplinary solutions, including clinical research, trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and support for pharma, biotech, and medical device products, serving clients primarily in Northern Europe with over 150 employees across offices in Denmark, Sweden, Germany, and the Netherlands.[2][3] In 2024, despite biotech funding challenges, KLIFO achieved positive EBITDA of DKK 4.9 million and equity of DKK 79.1 million, focusing growth on premium consulting and clinical trial supply while scaling back full-service CRO exposure.[1]
Founded in 1994 in Denmark as a Clinical Research Organisation (CRO), KLIFO evolved under Alejandra Mørk, who acquired the company in 2008 and became CEO, transforming it into an integrated drug development consultancy.[2][4] Mørk, a former senior pharma executive, addressed gaps in drug execution—such as flawed trials and strategies—spotted during the late 2000s biotech boom, while Christina Vinum led the 2008 launch of its Clinical Trial Supply unit to ensure reliable supply chains.[4] Key expansions included offices in Sweden, the acquisition of Munich-based Medicomp GmbH and Dutch MediServ, growing operations across Northern Europe; in recent years, Gilde Healthcare acquired a majority stake to fuel international ambitions.[2]
KLIFO rides the wave of biotech innovation in Medicon Valley—one of Europe's largest life science clusters—where promising therapies often falter due to execution flaws rather than science, providing critical support to bridge clinical development gaps.[2][4] Timing aligns with persistent biotech funding constraints, where efficient, risk-mitigating consultancies like KLIFO enable leaner paths to approval, bolstered by market forces favoring specialized Northern European hubs with multidisciplinary capabilities.[1][3] It influences the ecosystem by partnering with pharmacos, biotechs, and medtech firms, fostering innovation through reliable trial supply and consulting that accelerates global product launches and reduces failure rates.[2][5]
KLIFO's strategic pivot—bolstered by 2024 investments, Gilde's support, and a strong order book—positions it for accelerated 2025 growth via M&A, partnerships, and expanded premium consulting.[1][2] Trends like biotech funding recovery, rising demand for efficient supply chains, and regulatory complexities will shape its path, potentially evolving its influence from regional leader to broader European player in integrated drug services. This builds on its core strength: turning insight into impact, ensuring more therapies reach patients despite headwinds.
